CL
Therapeutic Areas
TORL BioTherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TORL-1-23 | CLDN6+ Solid Tumors (e.g., Platinum-Resistant Ovarian Cancer) | Phase 2 |
| TORL-4-500 | DLK1+ Solid Tumors | Phase 1 |
| TORL-5-700 | Undisclosed Hematologic Malignancy | Phase 1 |
Leadership Team at TORL BioTherapeutics
MA
Mark Alles
Chairman & CEO
DS
Dennis Slamon, MD, PhD
Director, Co-Founder
AM
Aran Maree, MD
Chief Medical Officer
DL
Dave Licata
Chief Financial Officer, Chief Technology Officer, Director, Co-Founder
SR
Steve Ritland, PhD
Chief Scientific Officer